Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 65.0 Cr.
- Current Price ₹ 44.4
- High / Low ₹ 64.4 / 43.0
- Stock P/E 13.3
- Book Value ₹ 48.0
- Dividend Yield 0.00 %
- ROCE 11.1 %
- ROE 8.47 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.92 times its book value
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 2.36 | 4.27 | 10.40 | 37.66 | 52.57 | 58.74 | |
| 1.98 | 4.95 | 14.91 | 34.89 | 45.24 | 50.90 | |
| Operating Profit | 0.38 | -0.68 | -4.51 | 2.77 | 7.33 | 7.84 |
| OPM % | 16.10% | -15.93% | -43.37% | 7.36% | 13.94% | 13.35% |
| 0.04 | 0.04 | 0.01 | 1.20 | 1.16 | 1.23 | |
| Interest | 0.09 | 0.19 | 0.24 | 0.17 | 0.36 | 0.42 |
| Depreciation | 0.08 | 0.17 | 0.19 | 0.74 | 1.02 | 1.02 |
| Profit before tax | 0.25 | -1.00 | -4.93 | 3.06 | 7.11 | 7.63 |
| Tax % | 20.00% | -21.00% | -26.77% | 24.51% | 25.18% | |
| 0.20 | -0.78 | -3.62 | 2.32 | 5.32 | 5.73 | |
| EPS in Rs | 0.31 | -0.69 | -2.98 | 1.86 | 3.71 | 3.49 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 102% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -10% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 3.82 | 3.82 | 3.82 | 13.76 | 14.35 |
| Reserves | 1.74 | 1.10 | -0.87 | 43.03 | 54.44 |
| 1.74 | 1.37 | 1.61 | 2.76 | 4.73 | |
| 3.66 | 3.01 | 7.49 | 6.56 | 15.85 | |
| Total Liabilities | 10.96 | 9.30 | 12.05 | 66.11 | 89.37 |
| 1.68 | 1.71 | 1.75 | 23.12 | 22.10 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 3.17 | 1.72 | 0.10 | 7.15 | 15.29 |
| 6.11 | 5.87 | 10.20 | 35.84 | 51.98 | |
| Total Assets | 10.96 | 9.30 | 12.05 | 66.11 | 89.37 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.00 | 0.16 | -0.33 | 2.78 | 2.25 | |
| 0.00 | -0.30 | -0.71 | -11.30 | -8.63 | |
| 0.00 | -0.55 | 0.95 | 6.96 | 8.21 | |
| Net Cash Flow | 0.00 | -0.69 | -0.09 | -1.57 | 1.83 |
| Free Cash Flow | 0.00 | -0.04 | -0.56 | -7.51 | 2.25 |
| CFO/OP | 0% | -26% | 7% | 112% | 50% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 225.81 | 73.51 | 41.41 | 104.58 | 140.39 |
| Inventory Days | 819.93 | 287.76 | 153.96 | 64.48 | 35.09 |
| Days Payable | 605.69 | 174.40 | 184.66 | 36.99 | 111.03 |
| Cash Conversion Cycle | 440.04 | 186.87 | 10.72 | 132.07 | 64.46 |
| Working Capital Days | 80.42 | -1.71 | -151.62 | 143.73 | 127.89 |
| ROCE % | -11.83% | -105.39% | 11.12% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Export Revenue Share % ・Standalone data |
|
||||
| Number of Permanent Employees count ・Standalone data |
|||||
Extracted by Screener AI
Documents
Announcements
-
Compliance Under Regulation 36 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('The Listing Regulations')
- Eiko Lifesciences sent AGM notice; 49th AGM on 22 September 2026, with e-voting from 19-21 September.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for 49th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday, 22nd day of September, 2026 at 04:00 P.M. …
- Reg. 34 (1) Annual Report.
- 49Th Annual General Meeting Of The Company Will Be Held On Tuesday, 22Nd Day Of September, 2026 At 04:00 P.M. (IST) Through Video Conferencing/ Other Audio Visual Means.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
- Ms. Hasti Doshi resigned as Independent Director effective 24 August 2026 due to career commitments.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.